Research & Technology
EmstoPA is an antibody-based reversal agent to treat bleeding caused by tPA, the pivotal protein controlling blood clot removal (thrombolysis). Excess tPA drives thrombolysis and leads to severe bleeding in more than 4.5 million patients per year.
EmstoPA has been developed for the emergency cessation of tPA activity thus enabling the balance between the clotting and thrombolytic systems to be restored.
EmstoPA is the first and only targeted therapy to inhibit tPA induced bleeding and has been shown in animal models to be effective at stopping bleeding.
EmstoPA will be a first in class biotechnology product which addresses an area of high unmet medical need, for which there is no existing standard of care. It is currently the only specific antidote in development for tPA induced hemorrhage.